Interestingly, the targeting of PI3K/mTOR signaling pathway by dactolisib decreased the UBE2C levels in all cancer cell lines (Figure 5G), regardless of their different levels of PI3K activation (Supplementary Figure S5I). This evidence concerns the gene UBE2C and cancer.